TBTimo Boelsums

Timo Boelsums

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Timo Boelsums has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Authors’ response: Added value of backward contact tracing for COVID-19

    by Timo Louis Boelsums, Maaike Buskermolen

    Eurosurveillance.org is the online home of Eurosurveillance, Europe's journal on infectious disease surveillance, epidemiology, prevention and control.

  • Open Access

    The value of manual backward contact tracing to control COVID-19 in practice, the Netherlands, February to March 2021: a pilot study

    by Timo Louis Boelsums, Inge Anna Theresia van de Luitgaarden, Jane Whelan, Hanna Poell, Charlotte Maria Hoffman, Ewout Fanoy, Maaike Buskermolen, Jan Hendrik Richardus

    Background: Contact tracing has been a key component of COVID-19 outbreak control. Backward contact tracing (BCT) aims to trace the source that infected the index case and, thereafter, the cases infected by the source. Modelling studies have suggested BCT will substantially reduce SARS-CoV-2 transmission in addition to forward contact tracing. Aim: To assess the feasibility and impact of adding BCT in practice. Methods: We identified COVID-19 cases who were already registered in the electronic database between 19 February and 10 March 2021 for routine contact tracing at the Public Health Service (PHS) of Rotterdam-Rijnmond, the Netherlands (pop. 1.3 million). We investigated if, through a structured questionnaire by dedicated contact tracers, we could trace additional sources and cases infected by these sources. Potential sources identified by the index were approached to trace the source’s contacts. We evaluated the number of source contacts that could be additionally quarantined. Results: Of 7,448 COVID-19 cases interviewed in the study period, 47% (n = 3,497) indicated a source that was already registered as a case in the PHS electronic database. A potential, not yet registered source was traced in 13% (n = 979). Backward contact tracing was possible in 62 of 979 cases, from whom an additional 133 potential sources were traced, and four were eligible for tracing of source contacts. Two additional contacts traced had to stay in quarantine for 1 day. No new COVID-19 cases were confirmed. Conclusions: The addition of manual BCT to control the COVID-19 pandemic did not provide added value in our study setting.


  • Open Access

    Community-based SARS-CoV-2 testing in low-income neighbourhoods in Rotterdam: Results from a pilot study

    by Martijn Vink, Zsófia Iglói, Ewout B Fanoy, Janko van Beek, Timo Boelsums, Miranda de Graaf, Helene A.C.M. Voeten, Richard Molenkamp, Marion Pg Koopmans, Fraukje Ef Mevissen

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in 2019 [1] and caused the largest pandemic of modern times [2]. Two years since the beginning of this pandemic, a vast amount of knowledge about the virus has been acquired and numerous diagnostic tests have been developed [3]. Diagnostic capacities and large test facilities have been […]


  • Open Access

    From more testing to smart testing: data-guided SARS-CoV-2 testing choices, the Netherlands, May to September 2020

    by Janko van Beek, Zsofia Igloi, Timo Boelsums, Ewout Fanoy, Hannelore Gotz, Richard Molenkamp, Jeroen van Kampen, Corine GeurtsvanKessel, Annemiek A van der Eijk, David van de Vijver, et al.

    Background: SARS-CoV-2 RT-PCR assays are more sensitive than rapid antigen detection assays (RDT) and can detect viral RNA even after an individual is no longer infectious. RDT can reduce the time to test and the results might better correlate with infectiousness. Aim: We assessed the ability of five RDT to identify infectious COVID-19 cases and systematically recorded the turnaround time of RT-PCR testing. Methods: Sensitivity of RDT was determined using a serially diluted SARS-CoV-2 stock with known viral RNA concentration. The probability of detecting infectious virus at a given viral load was calculated using logistic regression of viral RNA concentration and matched culture results of 78 specimens from randomly selected non-hospitalised cases. The probability of each RDT to detect infectious cases was calculated as the sum of the projected probabilities for viral isolation success for every viral RNA load found at the time of diagnosis in 1,739 confirmed non-hospitalised COVID-19 cases. Results: The distribution of quantification cycle values and estimated RNA loads for patients reporting to drive-through testing was skewed to high RNA loads. With the most sensitive RDT (Abbott and SD Biosensor), 97.30% (range: 88.65–99.77) of infectious individuals would be detected. This decreased to 92.73% (range: 60.30–99.77) for Coris BioConcept and GenBody, and 75.53% (range: 17.55–99.77) for RapiGEN. Only 32.9% of RT-PCR results were available on the same day as specimen collection. Conclusion: The most sensitive RDT detected infectious COVID-19 cases with high sensitivity and may considerably improve containment through more rapid isolation and contact tracing.


  • Open Access

    Outbreaks of mumps genotype G viruses in the Netherlands between October 2019 and March 2020: clusters associated with multiple introductions

    by Anita A. Shah, Rogier Bodewes, Linda Reijnen, Timo Boelsums, Claudia M. Weller, Ewout B. Fanoy, Irene K. Veldhuijzen

    From October 2019–March 2020, several clusters of mumps cases were identified in the Netherlands. Our objective was to describe cluster-associated mumps virus transmission using epidemiological and molecular information in order to help future mumps outbreak investigation and control efforts. An epidemiological cluster includes ≥ 2 mumps cases with at least an epidemiological-link to a laboratory-confirmed mumps case. A molecular group includes ≥ 2 mumps cases with identical mumps virus sequences. Cases with symptom onset date between 1 October 2019 and 31 March 2020 reported through the National Notifiable Diseases Surveillance System were included. We described epidemiological and clinical characteristics of mumps cases. Sequence data was obtained from selected regions of mumps virus genomes (2270 nucleotides). Associations between epidemiological and molecular information were investigated. In total, 102 mumps cases were notified (90% laboratory-confirmed, 10% epidemiologically-linked). 71 out of 102 cases were identified as part of an epidemiological cluster and/or molecular group. Twenty-one (30%) of 71 cases were identified solely from epidemiological information, 25 (35%) solely from molecular surveillance, and 25 (35%) using both. Fourteen epidemiological clusters were identified containing a total of 46 (range: 2–12, median: 3) cases. Complete sequence data was obtained from 50 mumps genotype G viruses. Twelve molecular groups were identified containing 43 (range: 2–13) cases, dispersed geographically and timewise. Combined information grouped seven epidemiological clusters into two distinct molecular groups. The first lasting for 14 weeks, the other for 6. Additionally, one molecular group was detected, linked by geography and time but without an epidemiological-link. Combined epidemiological and molecular information indicated ongoing mumps virus transmission from multiple introductions for extended time periods. Sequence analysis provided valuable insights into epidemiological clustering. If combined information is available in a timely manner, this would improve outbreak detection, generate further insight into mumps transmission, and guide necessary control measures.


  • Open Access

    Diagnostic accuracy of rapid antigen tests in asymptomatic and presymptomatic close contacts of individuals with confirmed SARS-CoV-2 infection: cross sectional study

    by Ewoud Schuit, Irene K Veldhuijzen, Roderick P Venekamp, Wouter van Den Bijllaardt, Suzan D Pas, Esther B Lodder, Richard Molenkamp, Corine H GeurtsvanKessel, Jans Velzing, Robin C Huisman, et al.

    Objective To assess the diagnostic test accuracy of two rapid antigen tests in asymptomatic and presymptomatic close contacts of people with SARS-CoV-2 infection on day 5 after exposure. Design Prospective cross sectional study. Setting Four public health service covid-19 test sites in the Netherlands. Participants 4274 consecutively included close contacts (identified through test-and-trace programme or contact tracing app) aged 16 years or older and asymptomatic for covid-19 when requesting a test. Main outcome measures Sensitivity, specificity, and positive and negative predictive values of Veritor System (Beckton Dickinson) and Biosensor (Roche Diagnostics) rapid antigen tests, with reverse-transcriptase polymerase chain reaction (RT-PCR) testing as reference standard. The viral load cut-off above which 95% of people with a positive RT-PCR test result were virus culture positive was used as a proxy of infectiousness. Results Of 2678 participants tested with Veritor, 233 (8.7%) had a RT-PCR confirmed SARS-CoV-2 infection of whom 149 were also detected by the rapid antigen test (sensitivity 63.9%, 95% confidence interval 57.4% to 70.1%). Of 1596 participants tested with Biosensor, 132 (8.3%) had a RT-PCR confirmed SARS-CoV-2 infection of whom 83 were detected by the rapid antigen test (sensitivity 62.9%, 54.0% to 71.1%). In those who were still asymptomatic at the time of sampling, sensitivity was 58.7% (51.1% to 66.0%) for Veritor (n=2317) and 59.4% (49.2% to 69.1%) for Biosensor (n=1414), and in those who developed symptoms were 84.2% (68.7% to 94.0%; n=219) for Veritor and 73.3% (54.1% to 87.7%; n=158) for Biosensor. When a viral load cut-off was applied for infectiouness (≥5.2 log10 SARS-CoV-2 E gene copies/mL), the overall sensitivity was 90.1% (84.2% to 94.4%) for Veritor and 86.8% (78.1% to 93.0%) for Biosensor, and 88.1% (80.5% to 93.5%) for Veritor and 85.1% (74.3% to 92.6%) for Biosensor, among those who remained asymptomatic throughout. Specificities were >99%, and positive and negative predictive values were >90% and >95%, for both rapid antigen tests in all analyses. Conclusions The sensitivities of both rapid antigen tests in asymptomatic and presymptomatic close contacts tested on day 5 onwards after close contact with an index case were more than 60%, increasing to more than 85% after a viral load cut-off was applied as a proxy for infectiousness.


  • Open Access

    From more testing to smart testing: data-guided SARS-CoV-2 testing choices

    by Janko van Beek, Zsofia Igloi, Timo Boelsums, Ewout Fanoy, Hannelore Gotz, Richard Molenkamp, Jeroen van Kampen, Corinne Geurtsvankessel, Annemiek van der Eijk, David van de Vijver, et al.

    We present an in-depth analysis of data from drive through testing stations using rapid antigen detection tests (RDT’s), RT-PCR and virus culture, to assess the ability of RDT’s to detect infectious cases. We show that the detection limits of five commercially available RDT’s differ considerably, impacting the translation into the detection of infectious cases. We recommend careful fit-for-purpose testing before implementation of antigen RDT’s in routine testing algorithms as part of the COVID-19 response.